- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03909113
Tolerability of Hypoallergenic Formula in Children With Cow's Milk Allergy (SINEALLII)
February 21, 2024 updated by: Roberto Berni Canani, MD, PhD, Federico II University
Tolerability of the New Hypoallergenic Formula in Children With IgE Mediated Cow's Milk Allergy
Cow's milk protein allergy is defined as an immunological reaction to one or more milk proteins.
A variety of symptoms can be suggestive for cow's milk protein allergy .
Cow's milk protein allergy is suspected clinically in 5-15% of infants, while most estimates of prevalence of cow's milk protein allergy vary from only 2 to 5 %.
Confusion regarding cow's milk protein allergy prevalence is often due to differences in study populations, study design and a lack of defined diagnostic criteria.
The importance of defined diagnostic criteria needs to be emphasised.
It precludes infants from an unnecessary diet and avoids delay in diagnosis, which can lead to malnutrition.
The treatment of cow's milk protein allergy is the dietary elimination of cow's milk proteins.
In non-breastfed infants and children less than 2 years of age, a substitute formula is mandatory as prescribed by several international scientific societies.
Extensively hydrolyzed formulas are used as therapeutic formulas.
An extensively hydrolysed formula is often a whey or casein based formula in which the protein has been chopped up in smaller pieces that are less allergenic.
Because of high cross-reactivity (up to 80%) and nutritional inadequacy, the use of any other animal milk or soy-based formula is precluded.The infant should be maintained on an elimination diet until the child is between 9-12 months of age or at least for 6 months, whichever occurs first.
In most cases, symptoms will improve substantially within 2-4 weeks if diagnosis is correct.
According to consensus in literature, a therapeutic formula is a formula tolerated by at least 90% (with 95% confidence) of cow's milk protein allergy infants.
The primary study outcome will be the evaluation of the hypoallergenicity of a new aminoacid based formula in children with confirmed immunoglobulin (Ig)E- mediated CMA.
According to the American Academy of Pediatrics (AAP) Subcommittee on Nutrition and Allergic Diseases a hypoallergenic formula must be tested in infants and children with hypersensitivity to cow's milk proteins, with findings verified by elimination-challenge tests under double-blind, placebo-controlled conditions (DBPCFC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Napoli
-
Portici, Napoli, Italy, 80055
- Rita Nocerino
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 3 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Consecutive patients aged 1-36 months with diagnosis of Immunoglobulin E-mediated cow milk allergy in the last 12 weeks,
- full and stable remission of allergy symptoms
- Written informed consent form collected by the parents.
Exclusion Criteria:
- Infant aged <1 months and >36 months,
- breast fed infants,
- other food allergies,
- other allergic diseases,
- evidence of non-IgE-mediated CMA,
- history of severe anaphylactic reaction,
- eosinophilic disorders of the gastrointestinal tract,
- chronic systemic diseases,
- congenital cardiac defects,
- active tuberculosis,
- autoimmune diseases,
- immunodeficiency,
- chronic inflammatory bowel diseases,
- celiac disease,
- cystic fibrosis,
- metabolic diseases,
- malignancy,
- chronic pulmonary diseases,
- malformations of the gastrointestinal and/or respiratory tract,
- use of systemic antibiotics or anti-mycotic drugs during 4 weeks before study entry;
- investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements;
- participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: amino acid based formula
|
amino acid based formula
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects tolerants to a new hypoallergenic formula demonstrated by oral food challenge with the new study formula
Time Frame: After one week from the oral food challenge
|
All subjects perform an oral food challenge with the new study formula.
If the infant not react to the new hypoallergenic formula during the oral food challenge, the subjects tolerate this product.
|
After one week from the oral food challenge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of body weight in children assuming amino acid based formula
Time Frame: after 180 days
|
In the absence of reaction to the new amino acid based formula, a subgroup of child (n=15) will continue the second part of the study, with an open-label feeding with amino acid based formula for 180 days.
|
after 180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2019
Primary Completion (Actual)
April 30, 2020
Study Completion (Actual)
May 31, 2020
Study Registration Dates
First Submitted
April 5, 2019
First Submitted That Met QC Criteria
April 8, 2019
First Posted (Actual)
April 9, 2019
Study Record Updates
Last Update Posted (Actual)
February 22, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 440/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy Milk
-
Martini Hospital GroningenRecruitingCow Milk Allergy | Food AllergyNetherlands
-
University GhentActive, not recruitingCow Milk Allergy | Food AllergyBelgium
-
Federico II UniversityUnknown
-
Federico II UniversityRecruiting
-
Société des Produits Nestlé (SPN)Completed
-
Assistance Publique - Hôpitaux de ParisESPCI ParisCompleted
-
University of Campinas, BrazilCompleted
-
Assiut UniversityUnknown
-
Edetec Indústria Alimentícia S.A.Federal University of Minas Gerais; Faculdade de Ciências Médicas de Minas...CompletedCow's Milk Allergy
Clinical Trials on amino acid based formula
-
United PharmaceuticalsCompleted
-
Nutricia ResearchTerminatedAllergy | Food AllergyUnited Kingdom, France, Germany
-
Federico II UniversityCompleted
-
Société des Produits Nestlé (SPN)Completed
-
Mead Johnson NutritionWithdrawnCow's Milk Allergy | Intolerance to Extensively Hydrolyzed Formulas | Intolerance to Breast MilkUnited Kingdom
-
Abbott NutritionCompleted
-
Dr. Schär AG / SPACompleted